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introduction
With rising health-care costs and a growth of pharmaceuti-
cal options, health professionals are continuously looking 
for better and more comprehensive methods to evaluate 
treatments. In recent years, the term “drug survival” (DS) has 
made its way through the field of dermatology. This method-
ological approach, which is based on regular Kaplan–Meier 
survival analysis, has its roots in rheumatology, where it was 
first described in 1991 (Wijnands et al., 1991). The method 
of DS has only relatively recently emerged in dermatology, 
with most publications limited to biological treatments for 
psoriasis. In addition, different synonyms have been used to 
describe DS, such as “drug retention,” “drug longevity” or 
the incorrectly used “drug adherence.” For these reasons, not 
all dermatologists may be familiar with this topic. 
 Our aim here is to provide an overview of the principles, 
purposes, and pitfalls of DS analysis to guide physicians in 
reading and interpreting DS studies. 
WHY uSE druG SurViVAL?
DS is a comprehensive outcome covering effectiveness, safety, 
and patients’ and doctors’ preferences. Identifying drugs with 
long survival rates as well as ways to prolong DS is therefore 
important. It is particularly suitable for chronic diseases that 
require long-term treatment.
WHAt iS druG SurViVAL?
In brief, DS is the time patients remain on a specific drug, 
investigated using the technique of survival analysis. Survival 
analysis is a method to analyze longitudinal data for the 
occurrence of an “event” (Bland and Altman, 1998; Wakkee 
et al., 2014). It is frequently used in oncology, and in this 
context, the event typically refers to the death of a patient or 
to disease progression (Yin et al., 2014). In DS, it refers to the 
actual discontinuation of a drug. Survival probabilities can 
be visualized with Kaplan–Meier curves, also widely known 
from oncology research (Figure 1). Figure 2 provides a trans-
lation of these classic curves to DS. 
HoW to PErForM druG SurViVAL?
If a patient experiences an event (drug discontinuation) at a spe-
•	 Aims	to	explore	the	time	on	drug	(drug	survival)	
	 using	the	Kaplan–Meier	survival	technique,	which	
	 allows	for	censoring.
•	 Applies	to	most	chronic	diseases	in	which	long	
	 drug	survival	is	desired	but	has	been	explored	
	 mainly	in	the	field	of	biologics.
•	 With	additional	Cox	regression	analysis,	predictors	
	 associated	with	drug	survival	can	be	identified.
•	
•	
•	 Factors	that	change	in	time,	such	as	the	number	of	
	 treatment	alternatives,	may	influence	drug	survival	
	 and	may	be	difficult	to	correct	for.
•	 Identified	predictors	provide	information	on	a	
	 potential	association,	but	do	not	automatically	
	 show	a	causal	link	with	drug	survival.
•	 Behavior	can	influence	drug	survival	significantly.	
	 However,	identifying	behavioral	factors	
	 influencing	survival	can	be	the	topic	of	interest	of	
	 a	study	as	well.
WHAt druG SurViVAL AnALYSiS doES
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Figure 1.  Melanoma-specific survival (log-rank P = 0.057). Example of 
classic Kaplan–Meier survival curve (oncology). Kaplan–Meier survival 
analysis for cutaneous melanoma overall survival by 0, 1, 2, and 3/4 NUG 
(number of unfavorable genotypes). The steps (events) in this survival curve 
refer to the death of a patient (Yin et al., 2014).
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(Wijnands et al., 1991). When different equivalent drugs are 
prescribed in equivalent patient populations, identifying those 
with the longest DS rates can be helpful in clinical decision 
making. Subanalyses split for different reasons of discontinu-
ation can be performed to deepen insight in DS. For instance, 
if patients frequently stop because of side effects, but also 
owing to ineffectiveness or disease remission, we should 
incorporate this important information in our (sub)analyses. If 
one is interested only in discontinuations due to a particular 
event, such as discontinuation because of side effects only, all 
discontinuations for other reasons should be censored.
 Second, the distillation of predictors that are associated 
with the DS of a drug is an important purpose. Useful predic-
tors for clinical practice can be used to select those patients 
who will benefit most from a certain drug. For instance, if we 
know that male sex is a strong positive predictor for drug sur-
vival of a certain drug, we could retain the drug for males and 
try to find an alternative drug for females. 
 Third, studying and comparing DS of different (dis-
ease) groups may provide insight into whether we can 
exchange knowledge between those groups. Comparisons 
of DS between disease groups have been published (e.g., 
DS of anti–tumor necrosis factor in three rheumatic diseas-
es) (Heiberg et al., 2008). Information from other diseases or 
specialties using the same drug is frequently adopted without 
the knowledge of whether this information is actually inter-
changeable.
 Finally, to improve comprehensiveness of DS, our group 
recently combined DS rates with a quality-of life-measure 
(DLQI) and named it “happy” drug survival (van den Reek et 
al., 2014). As we put effort in prolonging DS rates, we think 
it is also important to know whether being on drug is com-
patible with acceptable quality-of-life rates. Of course, other 
quality-of-life measures can be used instead of DLQI. 
 In dermatology, publications on DS have been mainly 
limited to evaluating biologicals in psoriasis. Recently, a study 
on fumaric acid esters in psoriasis was published, showing 
that this methodology can be adapted to other drugs in der-
matology (Ismail et al., 2014). 
cific time point in the study period, this leads to a step down in 
the Kaplan–Meier curve at that time point (Figure 2). If a patient 
has a shorter follow-up than the time frame of the survival anal-
ysis, the patient is “censored” and information is incorporated 
only up to the end of follow-up. Censoring is visualized by a tick 
mark in the curve (Figure 2). The ability to deal with censoring is 
an important feature of Kaplan–Meier survival analysis because 
information about patients with different follow-up periods can 
be fully incorporated in the model. The proportion of patients 
still “on drug” can be estimated for specific time intervals. For 
each time interval, the estimated probability that those who 
have survived from the beginning of that interval will survive 
to the end is calculated. This is a conditional probability (Bland 
and Altman, 1998). A general rule of thumb in survival analysis 
is that at least 10–20 events must be present in each survival 
curve for it to be valid. Survival curves of different groups, for 
instance, the DS of two different drugs, can be compared using 
the nonparametric log-rank test (Mantel–Cox test).
 Three assumptions must be fulfilled when calculating sur-
vival rates: (i) at any time point, the patients who are censored 
have the same (drug) survival prospects as the ones who con-
tinue, (ii) survival probabilities are stable throughout the whole 
period under study, and (iii) the time of event is precisely mea-
sured (Bland and Altman, 1998). 
 With survival analysis we can estimate the impact of 
explanatory variables on the risk of discontinuation of a drug. 
Thus, variables that are predictive of long or short DS can be 
identified. This can be done using multivariable Cox regression 
analysis (Wakkee et al., 2014). Of note, the number of variables 
that can enter a multivariable Cox regression model is limited 
to at most 10% of the number of observed events. Predictors 
are usually described with hazard ratios (HRs). HRs describe the 
chance of an event in one group divided by the chance of an 
event in the reference group. For instance, if males have an HR 
of 1.5, it means that they have 1.5 times more chance of shorter 
drug use than females (reference group). Vice versa, HRs less 
than 1 correspond to the chance of longer drug use. Moreover, 
Cox regression analysis can be used to correct for confound-
ing in DS. Adjusted survival curves can be obtained from Cox 
regression analysis, and can be presented next to the crude 
Kaplan–Meier survival curves.
WHEn cAn WE uSE A druG SurViVAL AnALYSiS?
DS studies have been used and analyzed for various purpos-
es: head-to-head comparisons between drugs were the first to 
be described in the literature and still form a major purpose 
Figure 2.  Explanation of Kaplan–Meier drug survival curve. Kaplan–Meier 
drug survival analysis. Explanation of features of a drug survival curve.
Figure 3.  Etanercept one-year drug survival (2005–2013) divided into 
four time frames. Kaplan–Meier drug survival analysis. Drug survival of 
etanercept, extracted from the BioCAPTURE registry, a Dutch daily practice 
biologics registry of psoriasis patients (van den Reek et al., 2014), divided 
for different time periods of initiation of etanercept. Historical occurrences 
thought to have had an influence on drug survival are described in the boxes.
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PitFALLS oF druG SurViVAL AnALYSiS
DS studies have certain limitations that should be considered 
when performing or reading such studies. 
Behavioral factors
DS is influenced by the behavior of physicians and patients. 
Some doctors or patients will directly stop a drug in case of side 
effects, whereas others tend to accept more side effects or risks 
and continue a drug. Also, decreased treatment adherence can 
indirectly influence drug survival: when nonadherent patients 
experience decreased effectiveness, doctors probably switch to 
a different drug because they may not be aware of nonadher-
ence. However, identifying behavioral factors that influence DS 
can be the topic of interest of a study as well and is not always 
a “pitfall.” 
influence of alternating trends
The number of available alternatives probably influences doc-
tors’ decisions (Aletaha, 2009; Heiberg et al., 2008). With a 
limited number of drugs to switch to, doctors will maximize 
their efforts to keep patients on a specific drug. We supported 
1. What is drug survival?
A. The half-life of a drug.
B. The time patients remain “on drug.”
C. The number of patients surviving treatment 
 with a drug.
D. The percentage of responders on a drug.
2. How can different follow-up times of patients be 
 combined in survival analysis?
A. The method of “censoring” can be applied, 
 incorporating all information until the end of 
 follow-up of each individual patient. 
B. All patients must have the same follow-up time; 
 otherwise, survival cannot be analyzed.
C. The patient with the shortest follow-up time is 
 leading; that period should be chosen as the 
 maximum duration of the survival analysis.
D. The method of last observation carried forward 
 should be applied; follow-up time of patients 
 with short follow-up can be extended with the 
 information available.
3. What can be used to estimate the required sample 
 size for a reliable survival analysis?
A. Survival studies can only be used for samples 
 with at least 100 patients.
B. The number of events determines the power of 
 survival analyses. A general rule of thumb in 
 survival analysis is that at least 10–20 events 
 must be present in each survival curve.
C. The number of patients determines the power of 
 survival analyses. At least 10–20 patients are 
 needed in each survival curve.
4. if a body weight below 100 kg is a predictor of drug 
 survival with a hazard ratio of 0.5 (95% confidence 
 interval 0.4–0.6), what does this mean?
A. Patients with a body weight <100 kg have a 
 lower chance to stop the drug than patients 
 weighing >100 kg. Thus, <100 kg is predictive 
 for long DS.
B. Patients with a body weight >100 kg have a 
 lower chance to stop the drug than patients 
 weighing <100 kg. Thus >100 kg is predictive 
 for long DS.
C. Patients with a body weight <100 kg have 0.5% 
 chance of discontinuing treatment within the 
 analyzed period.
D. Patients with a body weight >100 kg have 0.5% 
QuEStionS
This article has been approved for 1 hour of Category 1 CME credit. To 
take the quiz, with or without CME credit, follow the link under the “CME 
ACCREDITATION” heading.
For each question, more than one answer may be correct.
table 1.  Seven suggestions for harmonizing drug survival 
studies
Suggestion Example
1. Clearly describe population, 
group characteristics, time frame 
of analysis, reimbursement 
criteria, and existence of a drug 
preference policy
“All Dutch psoriasis patients eligible 
for biologics using the European 
reimbursement criteria starting 
adalimumab between 2011 and 
2013 were included. No drug pref-
erence policy existed. Patient and 
treatment characteristics are shown 
in Table x”
2. Diminish exclusion criteria and, 
instead, perform subanalyses 
of interest and/or multivariable 
regression analysis incorporating 
intended excluded groups
Do not exclude biologic-naive pa-
tients beforehand; instead, present 
all data and compare two groups 
(naive versus nonnaive) or analyze 
influence of naivety
3. Identify possible confounders 
and discuss their influence
Discuss the possible influence 
that the introduction of new drugs 
throughout the study period has 
on DS
4. Where possible, correct for 
confounders by means of multi-
variable regression analysis
If different drugs (etanercept and 
adalimumab) are compared, correct 
for existing differences between 
groups (e.g., biologics naivety or 
age)
5. Perform sensitivity analyses 
where needed
Perform analyses with two different 
cutoff points of ustekinumab (drug 
with a long half-life): date of last 
injection versus date of last injec-
tion + t)
6. Cut off analyses at the moment 
when a limited amount of 
patients becomes apparent at a 
specific time point
If only a few patients remain after 
5 years, censor the analysis at an 
earlier stage
7. Split for reasons of discontinua-
tion if possible
If patients discontinue mainly 
because of, for example, ineffec-
tiveness and side effects; perform 
sensitivity analyses for these reasons 
separately
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body weight is a predictor of lower DS, the patient could 
be advised to lose weight or use a higher dose of the drug. 
It must be noted that predictors only show association, not 
necessarily causation; the use of predictors as an interven-
tion therefore should be tested separately. It is important to 
be aware of the context of a predictor. For instance, if use 
of concomitant medication was found to be a predictor 
but only nonresponders received concomitant medication 
in that study, results will be biased. Importantly, no predic-
tors may be selected in a standard Cox model that have not 
been measured at baseline, or serious biases like these may 
occur (immortal time bias) (Ho et al., 2013). Time-dependent 
covariates might be part of the solution for this problem (Ho 
et al., 2013).
time of event
Because the event in a DS analysis depends on the date of 
discontinuation, problems arise when analyzing drugs with 
long half-lives. This is especially the case with the new-gen-
eration biologics (e.g., ustekinumab). In such cases, different 
cutoff points can be chosen for the event: date of last admin-
istration versus date of last administration plus t½. We think 
that both cutoff points should be analyzed separately to test 
for robustness because this problem conflicts with the third 
assumption of survival analysis mentioned above: “the time 
of event is precisely measured.”
concLuSion
DS studies have proven to be highly informative in the 
evaluation of rheumatological, dermatological, and 
 gastroenterological treatments. They have been mainly used 
for head-to-head comparisons of different biologics, as well 
as for the identification of predictors related to long DS of a 
specific drug. The methodology of DS could be adapted to 
other diseases and drugs in dermatology as well. DS analy-
sis is a relatively simple method requiring, in general, easily 
attainable information and is most suitable to analyze real-
life situations. DS is more comprehensive than classic effec-
tiveness analyses (PASI75). Moreover, in classic effectiveness 
analyses, disease flares, discontinuations, or dropouts fre-
quently lead to analytical problems.
 Because methodological designs and inclusion crite-
ria differ among published DS studies, these studies cannot 
always simply be compared. Moreover, it must be kept in 
mind that DS is influenced by behavioral factors and (dynam-
ic) circumstances, such as the availability of therapeutic alter-
natives; these factors can violate the general assumptions of 
survival analysis. In our opinion, correction for confounders 
or sensitivity analyses should be carried out wherever pos-
sible. 
 This paper provides an overview of the methodology, 
purposes, and limitations of DS specifically addressing the 
field of dermatology. To make future DS studies more compa-
rable and of high quality, we formulated seven suggestions to 
harmonize outcomes (Table 1). For indexing and to prevent 
false interpretations of the concept, we argue that the num-
ber of synonyms used should be reduced and we propose the 
worldwide adoption of the term “drug survival.”
this hypothesis with data of our psoriasis cohort by comparing 
the etanercept DS of different time periods (2005–2013) (Figure 
3). We think that important historical occurrences influenced 
survival, such as the change in reimbursement criteria or the 
introduction of new drugs. Evolving therapeutic aims could be 
another explanation for these DS changes (Aletaha and Smolen, 
2003). For example, in psoriasis this could be the tendency to 
pursue higher effectiveness (PASI90 instead of PASI75) or the 
tendency to incorporate quality-of-life measures in treatment 
decisions. 
 The influence of alternating trends is particularly important 
in head-to-head comparisons between agents that entered the 
market at different moments in time. For a fair comparison, 
we propose analyzing data from the moment that all agents 
were equally available. This advice is in line with the following 
assumption of survival analysis: “survival probabilities should 
be the same for subjects recruited at any time point in the study” 
(Bland and Altman, 1998). However, this advice may restrict 
the evaluation time and consequently the statistical power of 
the model because power depends on the number of events in 
each group. When one prefers to present all available data, sen-
sitivity analyses for restricted analyses should be presented as 
well to illustrate the impact of violating the above-mentioned 
 assumption.
Predictor identification
The process of predictor identification highly depends on 
the selection of candidate predictors and selection of study 
population beforehand. If in one study the selection of pre-
dictors that entered the Cox regression model differed from 
predictors in another study, the results cannot be directly 
compared. 
 The selection of candidate predictors should be based 
on their potential for clinical implementation. In general, 
baseline characteristics of patients are most informative 
because only these predictors can help the doctor at the 
moment of initiating a drug (e.g., age). Predictors are also of 
interest when they might increase DS. For instance, if high 
 chance of discontinuing treatment within the 
 analyzed period.
5. Which assumptions should be present in survival 
 analysis?
A. (i) At any time point, the patients who are 
 censored have the same survival prospects as 
 the ones who continue, (ii) survival probabilities 
 are stable throughout the whole study, and (iii) 
 the event corresponds with the specified time 
 and is not a raw estimation.
B. (i) At any time point, the patients who are 
 censored have the same survival prospects as 
 the ones who continue, (ii) survival probabilities 
 differ throughout the whole study, and (iii) the 
 event does not always correspond with the 
 specified time and is a raw estimation.
C. A and B are both incorrect.
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